Cheng Q - Search Results

1

The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy.

Shi C, Qin K, Lin A, Jiang A, Cheng Q, Liu Z, Zhang J, Luo P. Shi C, et al. Among authors: cheng q. J Exp Clin Cancer Res. 2022 Sep 7;41(1):268. doi: 10.1186/s13046-022-02469-0. J Exp Clin Cancer Res. 2022. PMID: 36071479 Free PMC article. Review.

2

Knockdown ATG4C inhibits gliomas progression and promotes temozolomide chemosensitivity by suppressing autophagic flux.

Wen ZP, Zeng WJ, Chen YH, Li H, Wang JY, Cheng Q, Yu J, Zhou HH, Liu ZZ, Xiao J, Chen XP. Wen ZP, et al. Among authors: cheng q. J Exp Clin Cancer Res. 2019 Jul 10;38(1):298. doi: 10.1186/s13046-019-1287-8. J Exp Clin Cancer Res. 2019. PMID: 31291988 Free PMC article.

3

PARP inhibitor resistance: the underlying mechanisms and clinical implications.

Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. Li H, et al. Among authors: cheng q. Mol Cancer. 2020 Jun 20;19(1):107. doi: 10.1186/s12943-020-01227-0. Mol Cancer. 2020. PMID: 32563252 Free PMC article. Review.

4

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.

Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, Zeng WJ, Liu Z, Cheng Q. Zhang H, et al. Among authors: cheng q. J Exp Clin Cancer Res. 2021 Jun 4;40(1):184. doi: 10.1186/s13046-021-01987-7. J Exp Clin Cancer Res. 2021. PMID: 34088360 Free PMC article. Review.

5

Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.

Xu S, Tang L, Liu Z, Luo C, Cheng Q. Xu S, et al. Among authors: cheng q. Front Immunol. 2021 Sep 30;12:731048. doi: 10.3389/fimmu.2021.731048. eCollection 2021. Front Immunol. 2021. PMID: 34659218 Free PMC article.

6

CAMSAP1 Mutation Correlates With Improved Prognosis in Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Yi Y, Qiu Z, Yao Z, Lin A, Qin Y, Sha R, Wei T, Wang Y, Cheng Q, Zhang J, Luo P, Shen W. Yi Y, et al. Among authors: cheng q. Front Cell Dev Biol. 2022 Jan 11;9:770811. doi: 10.3389/fcell.2021.770811. eCollection 2021. Front Cell Dev Biol. 2022. PMID: 35087829 Free PMC article.

7

Glioma targeted therapy: insight into future of molecular approaches.

Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, Ye W, Zeng W, Liu Z, Cheng Q. Yang K, et al. Among authors: cheng q. Mol Cancer. 2022 Feb 8;21(1):39. doi: 10.1186/s12943-022-01513-z. Mol Cancer. 2022. PMID: 35135556 Free PMC article. Review.

8

MHC-II Signature Correlates With Anti-Tumor Immunity and Predicts anti-PD-L1 Response of Bladder Cancer.

Yi R, Hong S, Zhang Y, Lin A, Ying H, Zou W, Wang Q, Wei T, Cheng Q, Zhu W, Luo P, Zhang J. Yi R, et al. Among authors: cheng q. Front Cell Dev Biol. 2022 Feb 11;10:757137. doi: 10.3389/fcell.2022.757137. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35223828 Free PMC article.

9

CAMOIP: a web server for comprehensive analysis on multi-omics of immunotherapy in pan-cancer.

Lin A, Qi C, Wei T, Li M, Cheng Q, Liu Z, Luo P, Zhang J. Lin A, et al. Among authors: cheng q. Brief Bioinform. 2022 May 13;23(3):bbac129. doi: 10.1093/bib/bbac129. Brief Bioinform. 2022. PMID: 35395670

10

Antigen Presentation Machinery Signature-Derived CALR Mediates Migration, Polarization of Macrophages in Glioma and Predicts Immunotherapy Response.

Chen R, Zhang H, Wu W, Li S, Wang Z, Dai Z, Liu Z, Zhang J, Luo P, Xia Z, Cheng Q. Chen R, et al. Among authors: cheng q. Front Immunol. 2022 Mar 28;13:833792. doi: 10.3389/fimmu.2022.833792. eCollection 2022. Front Immunol. 2022. PMID: 35418980 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,746 results

Search Page